Tianyin Pharmaceutical, Co., Inc. Announces Cash Dividend to Common Shareholders - Record Date January 29, 2010
January 11 2010 - 7:00AM
PR Newswire (US)
CHENGDU, China, Jan. 11 /PRNewswire-Asia-FirstCall/ -- Tianyin
Pharmaceutical Co., Inc. (NYSE Amex: TPI), a developer,
manufacturer and supplier of modernized traditional Chinese
medicine ("TCM") and generic pharmaceuticals in China, today
declared a quarterly cash dividend to be paid to its common stock
shareholders for the second fiscal quarter of 2010. The dividend of
2.5 cents per common share will be paid to shareholders of record
as of January 29, 2010, with the actual distribution occurring on
March 10, 2010. Dr. Jiang Guoqing, Tianyin's Chairman and Chief
Executive Officer, commented, "We are pleased to pay our quarterly
dividend. Our track record of consistent quarterly dividend
payments reflects the continued strength of our balance sheet, cash
flows, and future growth prospects, as well as our commitment to
sharing our profits with our shareholders." About Tianyin
Pharmaceuticals Tianyin is a manufacturer and supplier of
modernized Traditional Chinese Medicine ("TCM") in China. It was
established in 1994 and acquired by the current management team in
August 2003. It has a comprehensive product portfolio of 39
products, 22 of which are listed in the highly selective National
Medicine Catalog of the National Medical Insurance program. Tianyin
owns and operates two GMP manufacturing facilities and an R&D
platform supported by leading Chinese academic institutions. The
Company has a pipeline of 17 pharmaceutical products pending
approval. Tianyin has an extensive nationwide distribution network
throughout China with a sales force of 720 salespeople. Tianyin is
headquartered in Chengdu, Sichuan Province with two manufacturing
facilities and a total of 1,365 employees. For more information
about Tianyin, please visit http://www.tianyinpharma.com/ . Safe
Harbor Statement The Statements which are not historical facts
during the presentation are forward-looking statements that involve
certain risks and uncertainties including but not limited to risks
associated with the uncertainty of future financial results,
additional financing requirements, development of new products,
government approval processes, the impact of competitive products
or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's
filings with the Securities and Exchange Commission. For more
information, please contact: For the Company: Allen Tang, Ph.D.,
MBA, Assistant to the CEO in China Tel: +86-158-2122-5642 Email:
Investors: Mr. Matthew Hayden, HC International Tel:
+1-561-245-5155 Email: Web: http://www.hcinternational.net/
DATASOURCE: Tianyin Pharmaceutical Co., Inc. CONTACT: Allen Tang,
Ph.D., MBA, Assistant to the CEO China, +86-158-2122-5642, ;
Investors, Matthew Hayden, HC International, +1-561-245-5155, Web
site: http://www.tianyinpharma.com/
Copyright